(News Bulletin 247) – GSK welcomes the BC Supreme Court’s decision to dismiss a proposed class action lawsuit on behalf of a class of ranitidine users in Canada.
“The decision recognizes that after more than three years of extensive studies, the scientific consensus is that there is no consistent or reliable evidence that ranitidine (Zantac) increases the risk of any type of cancer,” the group says.
The Court said: ‘Given the uncontested evidence that neither ranitidine nor NDMA is reliably associated with an increased risk of cancer, and the lack of evidence that ranitidine or NDMA cause cancer in humans, the plaintiff has not raised a genuine adjudicable issue regarding injuries caused by the ingestion and/or purchase of ranitidine. ‘
GSK says the group will continue to vigorously defend class action lawsuits brought by ranitidine users that have been filed in Ontario and Quebec, as well as individual lawsuits brought by ranitidine users in Canada.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
